3 Mega Biotechs Leerink Loves

Leerink has released three new reports on some Outperform-rated big-name biotech stocks that the firm’s analysts like in coming months. Here’s a look at what the analysts had to say.

Gilead Sciences, Inc. GILD

Analyst Geoffrey Porges has a positive view toward the stock, saying, “[We're] positive about Gilead’s stock in part based on our favorable view of the company’s market leading HIV franchise.”

Porges doesn’t expect Gilead’s dominant position in the HIV space to be seriously challenged any time soon. He specifically mentioned Merck & Co., Inc. MRK’s Doravirine as a competitor that likely poses little threat to Gilead.

Related Link: Biotech Investors Shouldn't Fear Legislation, Even If Hillary Is President

Bristol-Myers Squibb Co BMY

Analyst Seamus Fernandez likes the company’s “leadership in the current immuno-oncology (I/O) space and in the next wave of IO/IO combination therapies.” In addition, Fernandez noted the rapid growth of Opdivo and the limited pricing risk the company faces as positives for the stock.

Teva Pharmaceutical Industries Ltd (ADR) TEVA

Analyst Jason Gerberry praised the acquisition of Allergan plc Ordinary Shares AGN’s generic drug pipeline, which includes g-Xifaxan. According to Gerberry, g-Xifaxan is “a blockbuster brand we’d expect TEVA to be able to launch (base case) in the 2025 timeframe.” While it’s uncertain how much competition the market will have, Gerberry anticipates limited g-Xifaxan ANDA filers.

Disclosure: The author holds no position in the stocks mentioned.